Please assess the completion status of the following clinical trial:

Trial Title: Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female child between 5 months and 17 months of age at the time of first vaccination.~* Written or oral, signed or thumb-printed and witnessed informed consent obtained from the parent(s)/guardian(s) of the child.~* Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol.~* Proof that child has received a full 3-dose regimen of licensed Hepatitis B vaccine in infancy.~Exclusion Criteria:~* Acute disease at the time of enrolment.~* Serious acute or chronic illness determined by clinical or physical examination and laboratory screening tests.~* Laboratory screening tests for haemoglobin, total white cell count, platelets, ALT and creatinine out of acceptable limits.~* Planned administration/administration of a vaccine (not in the scope of the study) within 30 days of the first dose of vaccine(s) with the exception of tetanus toxoid or scheduled Yellow fever or Measles vaccine.~* Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of the study vaccine, or planned use during the study period.~* Administration of immunoglobulins, blood transfusions or other blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Simultaneous participation in any other clinical trial;~* Previous participation in any other malaria vaccine trial;~* Any twins~* History of allergic reactions (significant IgE-mediated events) or anaphylaxis to previous immunizations.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.~* Any other findings that the investigator feels would increase the risk of having an adverse outcome from participation in the trial.

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 17 Months
- Healthy Volunteers: t

Study Arms:
- SB257049 F2 0-1 M Group (Type: EXPERIMENTAL): Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
- SB257049 F1 0-1 M Group (Type: EXPERIMENTAL): Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1-month schedule administered intramuscularly (IM) in the left deltoid muscle.
- SB257049 F2 0-1-2 M Group (Type: EXPERIMENTAL): Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
- SB257049 F1 0-1-2 M Group (Type: EXPERIMENTAL): Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.
- SB257049 F2 0-1-7 M Group (Type: EXPERIMENTAL): Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
- SB257049 F1 0-1-7 M Group (Type: ACTIVE_COMPARATOR): Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of SB257049 formulation 1 (F1) vaccine according to a 0, 1, 7-month schedule administered intramuscularly (IM) in the left deltoid muscle.
- Rabipur 0-1-2 M Group (Type: ACTIVE_COMPARATOR): Healthy infants between 5 and 17 months of age at the time of first vaccination received 3 doses of Rabipur vaccine according to a 0, 1, 2-month schedule administered intramuscularly (IM) in the left deltoid muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete